Pfizer to buy antibody developer

In a move to shore up its antibody pipeline, Pfizer announced that it intends to buy Bioren, a privately-held biotech based in San Carlos, California. The drug giant said the small company's antibody-development technologies will help it identify new antibodies and improve those it's already developing.

- read this AP story for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.